Program

 

PROGRAM AT-A-GLANCE

Monday, October 4, 2021 – all times in US Eastern Time

Session/Lecture

10:00 ET
Opening Remarks and ADDF Funding Opportunities
10:10
KEYNOTE: Recommendations for Exploratory Trials in Dementia
10:40
SESSION 1: CLINICAL TRIALS AND NOVEL APPROACHES FOR DEMENTIA
10:40
Session Overview
10:45
Phase 2 Study to Assess Safety and Target Engagement in AMYX0035 in AD
11:00
Phase 2a Exploratory Endpoint Trial in Mild-moderate Alzheimer’s for Small Molecule Modulation of the p75 Neurotrophin Receptor
11:15
Phase 1 Studies and Preparation of Clinical Phase 2 IND of MW150: Novel Stress Kinase Inhibitor Candidate
11:30
Strategies for Delivering Therapeutics across the Blood Brain Barrier
11:45
Panel Discussion
11:55
BREAK, POSTERS, EXHIBITS
12:30
START-UP FORUM
12:30
Investing in Dementia: Trends and Forward Outlook
12:40
Start-up presentations selected from submitted work
13:00
KEYNOTE: Clinical Validation for Plasma AB42/AB40 as a Biomarker for Alzheimer’s Disease Pathology
13:30
SESSION 2: ADVANCES IN FLUID BIOMARKERS
13:30
Session Overview
13:35
Brain-specific Tau in Blood as an Alzheimer’s Diagnostic
13:50
Misfolded Alpha-synuclein Aggregates in CSF as Diagnostic and Prognostic Markers for Dementia
14:05
TDN43
14:20
Blood-based Immune Biomarkers for Alzheimer's Disease Diagnosis and Its Early Detection
14:35
Panel Discussion
14:45
BREAK, POSTERS, EXHIBITS
15:00
SESSION 3: DRUG DEVELOPMENT APPROACHES FOR FRONTOTEMPORAL DEMENTIA
15:00
Session Overview
15:05
SUMO2 Mimetics as Innovative Inhibitors of Tau Toxicity in Pre-clinical Models of Frontotemporal Dementia
15:20
Development of a PIKFYVE Antisense Oligonucleotide (ASO) Treatment for FTD
15:35
Preclinical Pharmacokinetics and Pharmacodynamics of CT-526 in the Tauopathy Mouse Model
15:50
Panel Discussion
16:00
End of Day 1

Chair/Speaker

10:00 ET
Howard Fillit, MD - Alzheimer’s Drug Discovery Foundation
10:10
Jeffrey Cummings, MD, DSc - University of Las Vegas
10:40
SESSION 1: CLINICAL TRIALS AND NOVEL APPROACHES FOR DEMENTIA
10:40
Chair: Alessio Travaglia, PhD - Alzheimer’s Drug Discovery Foundation
10:45
Kent Leslie, MSc - Amylyx
11:00
Frank Longo, MD - PharmaTrophiX
11:15
Ottavio Arancio, MD, PhD - Columbia University/Neurokine
11:30
Georg Terstappen, PhD - Cambrian Biopharma
11:45
Chair and Presenters
11:55
BREAK, POSTERS, EXHIBITS
12:30
START-UP FORUM
12:30
Chair: Tracy Saxton, PhD - Dolby Family Ventures
12:40
Start-up presentations selected from submitted work
13:00
Kevin Yarasheski, PhD - C2N Diagnostics
13:30
SESSION 2: ADVANCES IN FLUID BIOMARKERS
13:30
Chair: Shobha Purushothama, PhD - Alzheimer’s Drug Discovery Foundation
13:35
Kaj Blennow, MD, PhD - University of Gothenburg
13:50
Russell Lebovitz, MD, PhD - Amprion
14:05
Qinwen Mao, MD, PhD - University of Utah
14:20
Thomas Montine, MD, PhD - Stanford University
14:35
Chair and Presenters
14:45
BREAK, POSTERS, EXHIBITS
15:00
SESSION 3: DRUG DEVELOPMENT APPROACHES FOR FRONTOTEMPORAL DEMENTIA
15:00
Chair: Penny Dacks, PhD - AFTD
15:05
Luana Fioriti, PhD - Plico Biotech
15:20
Wen-Hsuan Chang, PhD - Acurastem
15:35
Kent Werner, MD, PhD - Cogentis Therapeutics
15:50
Chair and Presenters
16:00
End of Day 1

Tuesday, October 5, 2021 – all times in US Eastern Time

Session/Lecture

10:00 ET
KEYNOTE: The Evolving Role of Biomarkers in Clinical Trials
10:00
SESSION 4: CLINICAL TRIALS 2--REPURPOSING APPROACHES FOR ALZHEIMER’S DISEASE
10:30
Session Overview
10:35
Effect of Candesartan on Prodromal Alzheimer’s Disease and Related Biomarkers
10:50
Repurposing Metformin for Prevention of Alzheimer’s Disease
11:05
Phase 2 Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer’s Disease
11:20
Panel Discussion
11:30
START-UP FORUM
11:30
Start-up presentations selected from submitted work
11:50
BREAK, POSTERS, EXHIBITS
12:15
SESSION 5: NEUROIMAGING AND DIGITAL BIOMARKERS FOR DEMENTIA
12:15
Session Overview
12:20
Circulating Brain-Enriched MicroRNAs as Peripheral Biomarkers of Neurodegeneration
12:35
Speech and Language as a Biomarker for Alzheimer’s Disease
12:50
Alzheimer’s Disease Digital Biomarker Discovery: From Concept to Research Implementation
13:05
Panel Discussion
13:15
SPECIAL LECTURE
13:45
Concluding Remarks
14:00
POSTERS AND NETWORKING
16:00
End of Conferece

Chair/Speaker

10:00 ET
Mark Mintun, MD - Avid Pharmaceuticals/Eli Lilly & Co.
10:00
SESSION 4: CLINICAL TRIALS 2--REPURPOSING APPROACHES FOR ALZHEIMER’S DISEASE
10:30
CHAIR: Alessio Travaglia, PhD - Alzheimer’s Drug Discovery Foundation
10:35
Ihab Hajjar, MD - Emory University
10:50
Miia Kivipelto, MD, PhD - Karolinska Institute
11:05
Miranda Orr, PhD - Wake Forest University
11:20
Chair and Panelists
11:30
START-UP FORUM
11:30
Start-up presentations selected from submitted work
11:50
BREAK, POSTERS, EXHIBITS
12:15
SESSION 5: NEUROIMAGING AND DIGITAL BIOMARKERS FOR DEMENTIA
12:15
CHAIR: Alessio Travaglia, PhD - Alzheimer’s Drug Discovery Foundation
12:20
Johannes Tauscher, MD - Takeda
12:35
Lampros Kourtis, PhD - Circadic
12:50
Rhoda Au, PhD - Boston University
13:05
Chair and Panelists
13:15
13:45
14:00
POSTERS AND NETWORKING
16:00
End of Conferece

REGISTRATION IS FREE!

PROGRAM DETAILS

CONFERENCE INTRODUCTION

Monday, October 4, 2021
10:00 US Eastern Time

Howard Fillit
Alzheimer’s Drug Discovery Foundation

 

Dr. Howard Fillit is ADDF’s Founding Executive Director and Chief Science Officer. His introduction will provide a welcome to our 22nd International Conference on Alzheimer’s Drug Discovery, a brief update on ADDF’s recent progress and will highlight the framework for this year’s meeting.

KEYNOTES

Jeffrey Cummings
UNLV

Kevin Yarasheski
C2N Diagnostics

Mark Mintun
Eli Lilly & Co., Inc.

Recommendations for Exploratory Trials in Dementia

Clinical Validation for Plasma AB42/AB40 as a Biomarker for Alzheimer’s Disease Pathology

The Evolving Role of Biomarkers in Clinical Trials

 

Monday, October 4, 2021
10:10 US Eastern Time

 

Monday, October 4, 2021
13:00 US Eastern Time

 

Tuesday, October 5, 2021
10:00 US Eastern Time

SESSIONS

SESSION I: CLINICAL TRIALS AND NOVEL APPROACHES FOR DEMENTIA

Mark Forman
ADDF

CHAIR
Session Overview

Kent Leslie
Amylyx

Phase 2 Study to Assess Safety and Target Engagement in AMYX0035 in AD

Frank Longo
PharmaTrophiX

Phase 2a Exploratory Endpoint Trial in Mild-moderate Alzheimer’s for Small Molecule Modulation of the p75 Neurotrophin Receptor

Ottavio Arancio
Neurokine

Phase 1 Studies and Preparation of Clinical Phase 2 IND of MW150: Novel Stress Kinase Inhibitor Candidate

Georg Terstappen
Cambrian Biopharma

Strategies for Delivering Therapeutics across the Blood Brain Barrier

 

Monday, October 4, 2021
10:40 US Eastern Time

 

Monday, October 4, 2021
10:45 US Eastern Time

 

Monday, October 4, 2021
11:00 US Eastern Time

 

Monday, October 4, 2021
11:15 US Eastern Time

 

Monday, October 4, 2021
11:30 US Eastern Time

PANEL DISCUSSION – SESSION I

Monday, October 4, 2021
11:45 – 11:55 US Eastern Time

POSTER SESSION/BREAK

This session will feature research from early investigators in the academic community focused on drug development for Alzheimer’s and related dementias.

Monday, October 4, 2021
11:55 – 12:30 US Eastern Time

START-UP FORUM

This session will feature drug development programs being pursued by start-up companies.

Tracy Saxton
Dolby Family Ventures

CHAIR
Investing in Dementia: Trends and Forward Outlook

 

Monday, October 4, 2021
12:30 – 13:00 US Eastern Time

SESSION II: ADVANCES IN FLUID BIOMARKERS

Shobha Purushothama
ADDF

CHAIR
Session Overview

Kaj Blennow
Univ. of Gothenburg

Brain-specific Tau in Blood as an Alzheimer’s Diagnostic

Russell Lebovitz
Amprion

Benfotiamine in Alzheimer’s Disease: A Pilot Study

Qinwen Mao
University of Utah

TDP43

Thomas Montine
Stanford University

Blood-based Immune Biomarkers for Alzheimer’s Disease Diagnosis and Its Early Detection

 

Monday, October 4, 2021
13:30 US Eastern Time

 

Monday, October 4, 2021
13:35 US Eastern Time

 

Monday, October 4, 2021
13:50 US Eastern Time

 

Monday, October 4, 2021
14:05 US Eastern Time

 

Monday, October 4, 2021
14:20 US Eastern Time

PANEL DISCUSSION – SESSION II

Monday, October 4, 2021
14:20 – 14:30 US Eastern Time

POSTER SESSION/BREAK

Monday, October 4, 2021
14:45 – 15:00 US Eastern Time

SESSION III: DRUG DEVELOPMENT APPROACHES FOR FRONTOTEMPORAL DEMENTIA

Penny Dacks
AFTD

CHAIR
Session Overview

Luana Fioriti
Plico Biotech

SUMO2 Mimetics as Innovative Inhibitors of Tau Toxicity in Pre-clinical Models of Frontotemporal Dementia

Wen-Hsuan Chang
Acurastem

Development of a PIKFYVE Antisense Oligonucleotide (ASO) Treatment for FTD

Kent Werner
Cogentis Therapeutics

APOE4 Leads to Breakdown in the Blood-brain Barrier Predicting Cognitive Decline

 

Monday, October 4, 2021
15:00 US Eastern Time

 

Monday, October 4, 2021
15:05 US Eastern Time

 

Monday, October 4, 2021
15:20 US Eastern Time

 

Monday, October 4, 2021
15:35 US Eastern Time

PANEL DISCUSSION – SESSION III

Monday, October 4, 2021
15:50 – 16:00 US Eastern Time

SESSION IV: CLINICAL TRIALS 2–REPURPOSING APPROACHES FOR ALZHEIMER’S DISEASE

Alessio Travaglia
ADDF

CHAIR
Session Overview

Ihab Hajjar
Emory University

Novel Positive Allosteric Modulators of the Alpha1A-Adrenergic Receptor to Treat Alzheimer’s Disease

Miia Kivipelto
Karolinska Institute

Repurposing Metformin for Prevention of Alzheimer’s Disease

Miranda Orr
Wake Forest University

Phase 2 Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer’s Disease

 

Tuesday, October 5, 2021
10:30 US Eastern Time

 

Tuesday, October 5, 2021
10:35 US Eastern Time

 

Tuesday, October 5, 2021
10:50 US Eastern Time

 

Tuesday, October 5, 2021
11:05 US Eastern Time

PANEL DISCUSSION – SESSION IV

Tuesday, October 5, 2021
11:20 – 11:30 US Eastern Time

START-UP FORUM

Tuesday, October 5, 2021
11:30 – 11:50 US Eastern Time

POSTER SESSION/BREAK

Tuesday, October 5, 2021
11:50 – 12:15 US Eastern Time

SESSION V: NEUROIMAGING AND DIGITAL BIOMARKERS FOR DEMENTIA

Nicole Bjorklund
ADDF

CHAIR
Session Overview

Johannes Tauscher
Takeda

Circulating Brain-Enriched MicroRNAs as Peripheral Biomarkers of Neurodegeneration

Lampros Kourtis
Circadic

Speech and Language as a Biomarker for Alzheimer’s

Rhoda Au
Boston University

Alzheimer’s Disease Digital Biomarker Discovery: From Concept to Research Implementation

 

Tuesday, October 4, 2021
12:15 US Eastern Time

 

Tuesday, October 4, 2021
12:20 US Eastern Time

 

Tuesday, October 5, 2021
12:35 US Eastern Time

 

Tuesday, October 4, 2021
12:50 US Eastern Time

PANEL DISCUSSION – SESSION V

Tuesday, October 5, 2021
13:05 – 13:15 US Eastern Time

SPECIAL LECTURE

Tuesday, October 5, 2021
13:15 – 13:45 US Eastern Time

CONCLUSIONS

Tuesday, October 5, 2021
13:45 – 14:00 US Eastern Time

NETWORKING/POSTERS

Tuesday, October 6, 2020
14:00 – 16:00 US Eastern Time